Linscomb Wealth Inc. Sells 61,733 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Linscomb Wealth Inc. cut its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 72.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,714 shares of the company’s stock after selling 61,733 shares during the quarter. Linscomb Wealth Inc.’s holdings in Elanco Animal Health were worth $287,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of ELAN. AM Squared Ltd purchased a new stake in shares of Elanco Animal Health during the 3rd quarter valued at $34,000. Wilmington Savings Fund Society FSB purchased a new stake in Elanco Animal Health during the third quarter valued at about $35,000. Farther Finance Advisors LLC lifted its stake in Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after purchasing an additional 2,044 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after purchasing an additional 1,601 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Elanco Animal Health by 2,129.2% in the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after purchasing an additional 3,790 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Up 2.4 %

Shares of ELAN opened at $11.19 on Friday. The stock has a market capitalization of $5.53 billion, a P/E ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health Incorporated has a twelve month low of $10.20 and a twelve month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $11.71 and a two-hundred day simple moving average of $13.03.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the prior year, the company posted $0.08 earnings per share. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday. Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Finally, Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and a consensus target price of $15.83.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.